Nutriband Inc. (NASDAQ: NTRB) Sees Price Target Increase to $15 After AVERSA Fentanyl Manufacturing Achievement

Nutriband Inc. (NASDAQ: NTRB) has achieved a significant milestone with the successful completion of commercial manufacturing and scale-up for its AVERSA Fentanyl abuse-deterrent transdermal patch, leading to a revised price target of $15 by Noble Capital Markets. This development is a pivotal moment for Nutriband, enabling the company to move forward with the production of clinical supplies and the submission of an Investigational New Drug (IND) application for a Phase 1 trial. The AVERSA program, which follows the 505(b)(2) regulatory pathway, is considered low risk by analysts, with a single Phase 1 study required to demonstrate the patch's reduced appeal to recreational drug users.

Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, has adjusted his FY2027 EPS forecast for Nutriband to $1.57, citing the company's adherence to its projected timeline and the avoidance of an anticipated equity raise in Q1 2025. Sales are expected to commence in FY2027, with the New Drug Application (NDA) submission projected between late 2025 and early 2026. This progress underscores the potential of AVERSA technology to address the critical issue of drug abuse and misuse, offering a safer alternative for patients requiring transdermal fentanyl therapy.

For further details on the report, visit https://ibn.fm/IWkz5. Nutriband's advancement with the AVERSA Fentanyl patch represents a notable step forward in the development of abuse-deterrent pharmaceuticals, highlighting the company's commitment to innovation in the face of the opioid crisis.